Cascade coordinating center
Active Cooperative Agreement Awarded Last action
- Award ID
- U24CA275417
- Recipient
-
Frontier Science & Technology Research Foundation, Inc. UEI JJKDG25RVFE5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,796,824
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 88% complete
- Place of performance
- Snyder, NY 14226, USA
Award details come from USAspending.gov.
Description
- Abstract
- Women living with HIV (WLWH) have a higher risk for acquisition, persistence, and progression of cervical human papillomavirus (HPV) to precancerous lesions, which, in the absence of effective screening and treatment services, can progress to invasive cancer at five-to-six times higher rates than in women without HIV. The massive global mobilization of humanitarian resources spanning over the past couple of decades, through initiatives such as the US president's emergency plan for aids relief (PEPFAR), has resulted in millions of WLWH in low- and middle-income countries (LMICS) now accessing affordable antiretroviral therapy and consequently living longer lives. Yet, their risk for cervical cancer continues unabated since effective screening and pre-cancer treatment services remain unavailable in most LMICS. The HIV/cervical cancer prevention "cascade" clinical trials network plans to conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to optimize the cervical cancer screening, management, and pre-cancer treatment cascade for WLWH. These clinical trials will be conducted in intended- use environments in resource-constrained settings in LMICS and in regions with health disparities in the united states. The cascade network will have four major scientific focus areas: increasing screening uptake, improving management of screen positives, facilitating pre-cancer treatment access, and optimizing pre-cancer treatment for cervical cancer prevention in WLWH. The cascade network clinical trials will focus on the measurement of the clinical effectiveness of interventions in intended use settings while gathering crucial information informing the implementation and scale-up of such interventions across the cascade of screening and pre-cancer treatment for WLWH. Such hybrid effectiveness-implementation designs will primarily focus on clinical effectiveness endpoints such as HPV positivity rates and/or pre-cancer detection/incidence/recurrence rates and will secondarily gather data on implementation-informing aspects such as costs, acceptability, and intervention fidelity while studying implementation strategy. To support the cascade clinical trials network in partnership with the NCI's division of cancer prevention, cascade research bases and cascade clinical sites, the cascade network coordinating center will (I) provide overall network coordination and facilitate scientific review of network clinical trial concepts and protocols, (II) provide centralized support for data management for network clinical trials, and (III) conduct independent risk-appropriate auditing of network clinical trials. The cascade network coordinating center will serve as the organizational and coordination hub for the cascade network and provide multi-disciplinary expertise in program and operations management, clinical research informatics/information technology, and clinical trials auditing.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,381,727 | |
| Amendment | $1,403,040 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $990,038 | |
| Amendment | $990,038 | |
| Amendment | $990,038 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,416,880 | |
| Amendment | $1,416,880 | |
| Amendment | $1,416,880 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $450,000 | |
| Amendment | $450,000 | |
| Amendment | $450,000 | |
| Amendment | $450,000 | |
| Amendment | $997,101 | |
| Amendment | $997,101 | |
| Original award | $997,101 |
Show all 29
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of North Carolina At Chapel Hill | $75,340 | |
| The Regents Of The University Of California. San Francisco | $392,895 | |
| Centro Comprensivo De Cancer De La Universidad De Puerto Rico | $45,749 | |
| University Of California, San Diego | $48,407 | |
| University Of California, LOS Angeles | $188,797 | |
| University Of California, LOS Angeles | $47,077 | |
| University Of Wisconsin System | $1,021,754 | |
| H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. | $311,842 | |
| University Of California, LOS Angeles | $8,652 | |
| University Of California, LOS Angeles | $42,156 | |
| University Of Wisconsin System | $262,369 | |
| University Of California, LOS Angeles | $42,773 |
Show all 12
Quick answers
Who received award U24CA275417?
U24CA275417 was awarded to Frontier Science & Technology Research Foundation, Inc. by National Cancer Institute (National Institutes of Health) on September 7, 2022.
How much is award U24CA275417 worth?
$14,796,824 has been obligated on U24CA275417.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award